Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
M.OlsenL
and Bickel, W.K
Enrolled patients were randomized in a 5:1 ratio to receive either tirzepatide or matched placebo by once-weekly (QW) subcutaneous (SC) injection in one of two cohorts: in Cohort 1 (2.510.0 mg), patients assigned to tirzepatide received 2.5 mg for the first 4 weeks, with the dose increasing by a further 2.5 mg every 4 weeks, to the maximum dose of 10.0 mg
In the SURPASS clinical trials for type 2 diabetes, tirzepatide demonstrated substantial reductions in HbA1c levels (up to 2.07-2.46% at the 15mg dose), while the SURMOUNT-1 trial showed weight reductions of 15-20.9% in people with obesity without diabetes
Bulk up to gain muscle and cut to lose fat
